The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes

被引:39
|
作者
Younossi, Zobair M. [1 ,2 ,3 ]
Golabi, Pegah [1 ,2 ,3 ]
Price, Jillian Kallman [1 ,2 ]
Owrangi, Soroor [1 ]
Gundu-Rao, Nagashree [3 ]
Satchi, Romona [3 ]
Paik, James M. [1 ,2 ,3 ]
机构
[1] Inova Hlth Syst, Beatty Liver & Obes Res Program, Falls Church, VA USA
[2] Inova Fairfax Med Campus, Ctr Liver Dis, Dept Med, Falls Church, VA USA
[3] Global NASH Council, 2411 I St, Washington, DC 20037 USA
关键词
NAFLD; MASLD; NASH; MASH; Steatotic Liver Disease; T2D; BURDEN; METAANALYSIS; FIBROSIS; RISK; PREVALENCE; REGRESSION; NASH; BIAS;
D O I
10.1016/j.cgh.2024.03.006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction associated steatotic liver disease (MASLD), is closely associated with type 2 diabetes (T2D). Our aim was to estimate the most recent global prevalence of NAFLD/MASLD, nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction associated steatohepatitis (MASH), advanced fibrosis, and mortality among patients with T2D. METHODS: We systematically searched PubMed and Ovid MEDLINE for terms including NAFLD, NASH, and T2D published in 1990-2023 according to PRISMA. The meta-analysis was conducted using a random-effects model. Assessment of bias risk used the Joanna Briggs Institute appraisal tool. RESULTS: From 3134 studies included in the initial search, 123 studies (N = 2,224,144 patients with T2D) were eligible. Another 12 studies (N = 2733 T2D patients with liver biopsy) were eligible for histologic assessments. The global pooled prevalence of NAFLD/MASLD among patients with T2D was 65.33% (95% confidence interval, 62.35%-68.18%). This prevalence increased from 55.86% (42.38%-68.53%) in 1990-2004 to 68.81% (63.41%-73.74%) in 2016-2021 (P = .073). The highest NAFLD/MASLD prevalence among T2D patients was observed in Eastern Europe (80.62%, 75.72%-84.73%), followed by the Middle East (71.24%, 62.22%-78.84%), and was lowest in Africa (53.10%, 26.05%-78.44%). Among patients with liver biopsy data, the global pooled prevalence of NASH/MASH, significant fibrosis, and advanced fibrosis was 66.44% (56.61%-75.02%), 40.78% (24.24%-59.70%), and 15.49% (6.99%-30.99%), respectively. The pooled all-cause mortality was 16.79 per 1000 person-years (PY) (10.64-26.40), 4.19 per 1000 PY (1.34-7.05) for cardiac-specific mortality; 6.10 per 1000 PY (0.78-4.88) for extrahepatic cancer-specific fi c mortality; and 2.15 per 1000 PY (0.00-2.21) for liver-specific mortality. CONCLUSIONS: The prevalence of NAFLD/MASLD among T2D is high and growing. The majority of NAFLD/MASLD patients with T2D have NASH/MASH, and a significant fi cant proportion have advanced fibrosis.
引用
收藏
页码:1999 / 2010
页数:12
相关论文
共 50 条
  • [11] Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Brown, Gregory Thomas
    Kleiner, David E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08): : 1080 - 1086
  • [12] Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Takahashi, Yoshihisa
    Fukusato, Toshio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (42) : 15539 - 15548
  • [13] Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World
    Sayiner, Mehmet
    Koenig, Aaron
    Henry, Linda
    Younossi, Zobair M.
    CLINICS IN LIVER DISEASE, 2016, 20 (02) : 205 - +
  • [14] Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic steatohepatitis
    Manne, Vignan
    Handa, Priya
    Kowdley, Kris V.
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 23 - +
  • [15] Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Yoshihisa Takahashi
    Toshio Fukusato
    World Journal of Gastroenterology, 2014, (42) : 15539 - 15548
  • [16] Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Farah, Samira
    Thu Nguyen
    Kelsberg, Gary
    Safranek, Sarah
    AMERICAN FAMILY PHYSICIAN, 2019, 99 (04) : 262 - 263
  • [17] Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan
    Okanoue, Takeshi
    Umemura, Atsushi
    Yasui, Kohichiroh
    Itoh, Yoshito
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 153 - 162
  • [18] Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
    Carter, Danielle
    Dieterich, Douglas T.
    Chang, Charissa
    CLINICS IN LIVER DISEASE, 2018, 22 (01) : 213 - +
  • [19] The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
    Sharma, Mithun
    Mitnala, Shasikala
    Vishnubhotla, Ravi K.
    Mukherjee, Rathin
    Reddy, Duvvur N.
    Rao, Padaki N.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 5 (02) : 147 - 158
  • [20] NONALCOHOLIC FATTY LIVER DISEASE AND STEATOHEPATITIS
    Colak, Yasar
    Tuncer, Ilyas
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2010, 73 (03): : 85 - 91